My Companies
Notification
Account
Log Out
Login
Wanbury received ANVISA (Brazil FDA) CADIFA suitability approval for flagship Metformin HCl EP grade, its third consecutive ANVISA API approval enabling customers to use its APIs in formulations. Company said it has initiated talks with customers to increase volumes.
Wanbury Wins Rs15 Crore Mexico Tender Expands Saudi Metformin Business
Wanbury Secures Rivaroxaban EDQM Approval And Two USFDA DMF Clearances
Wanbury Tanuku Facility Receives USFDA Form 483 With Six Observations
Wanbury Board Approves Early Redemption of ₹180 Crore NCDs
Wanbury Trustee Releases 24.39% Pledge on Expert Chemicals Holding